InvestorsHub Logo
icon url

Bourbon_on_my_cornflakes

12/05/17 6:03 PM

#133008 RE: rocalinda #133007

great find Rocalinda! look just above Missling also:

Steven Kaminsky, PhD, Chief Science Officer, Rettsyndrome.org
Christopher U. Missling, PhD, President and Chief Executive Officer, Anavex Life Sciences Corp


THAT is definitive confirmation that we are one of the 5 CNS trials...if not more.

WE are on the front burner at the FDA and have their priority attention. Missling is doing a great job...just get it started now.
icon url

Investor2014

12/05/17 6:05 PM

#133009 RE: rocalinda #133007

Excellent thanks!

And

Steven Kaminsky, PhD, Chief Science Officer, Rettsyndrome.org

There too!
icon url

TTTav66

12/05/17 6:08 PM

#133010 RE: rocalinda #133007

This is the session description from this past year. This session was already held on February 14, 2017.

Page 6 of the 2017 Program:
https://www.bio.org/sites/default/files/2017CEO_eBrochure_Final.pdf

Or scroll down to 2017 PROGRAMMING:
https://www.bio.org/events/bio-ceo-investor-conference/program
icon url

plexrec

12/05/17 6:15 PM

#133011 RE: rocalinda #133007

roca....thanks---can you provide a link where this can be found ?--I tried and was unsuccessful !!! TIA
icon url

attilathehunt

12/06/17 9:02 AM

#133068 RE: rocalinda #133007

It sure seems like what they will be discussing are the challenges/obstacles we encountered with starting the Rett trial.

Since R&R is also at the conference, I wonder when they will get their base to start accumulating. If they have already, it is a small base.

It would be great if thy had some readout by then.